The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Developments include cell-based and recombinant DNA technologies. The global influenza vaccine market is projected to cross $14b by 2032, according to DelveInsight. The sector’s expansion is ...

Mal-ID – can decipher an individual’s immune system’s record of past infections and diseases, according to a new study, providing a powerful tool with the potential for diagnosing autoimmune disorders ...

Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

A class action lawsuit was filed against Caribou Biosciences Inc. (CRBU) by Levi & Korsinsky on December 24, 2024. The ...

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

Recent advances in the field of immunology suggest that innate immune cells (e.g. dendritic cells, NK cells, phagocytes) are capable of displaying a form of ...